Home / Business and Economy / Pharma Stock Soars After Landmark USFDA Approval for UTI Drug
Pharma Stock Soars After Landmark USFDA Approval for UTI Drug
1 Jun
Summary
- Wockhardt's share price hit an all-time high after USFDA approval for Zaynich.
- Zaynich is a novel intravenous antibiotic for adult complicated urinary tract infections.
- The drug targets drug-resistant bacteria, addressing a significant US health concern.
Wockhardt's stock reached an all-time high, climbing 19 per cent on Monday after receiving US FDA approval for Zaynich (cefepime and zidebactam). This novel intravenous antibiotic is designed to treat complicated urinary tract infections, including pyelonephritis, in adults. The approval addresses a critical health need, as antimicrobial-resistant infections cause over 35,000 deaths annually in the US, with complicated UTIs accounting for more than 600,000 hospitalizations.
Zaynich represents a significant achievement as the first New Chemical Entity fully developed and commercialized by an Indian pharmaceutical company to gain US FDA approval. This breakthrough targets drug-resistant bacteria, a rapidly growing concern with limited treatment options. Wockhardt is also developing five other antibiotics, three of which are under priority review, further strengthening its pipeline of next-generation anti-infective solutions.
The company's financial performance has also seen positive developments, with ICRA upgrading its credit ratings. Wockhardt has focused on margin-accretive segments and cost rationalization, leading to an improved operating profit margin. The outlook for revenue remains healthy, driven by its formulations business and new product launches, including Zaynich, which has a projected global market potential of $9 billion.
